We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing.
- Authors
van Zyl-Smit RN; Pai M; Peprah K; Meldau R; Kieck J; Juritz J; Badri M; Zumla A; Sechi LA; Bateman ED; Dheda K; van Zyl-Smit, Richard N; Pai, Madhukar; Peprah, Kwaku; Meldau, Richard; Kieck, Jackie; Juritz, June; Badri, Motasim; Zumla, Alimuddin; Sechi, Leonardo A
- Abstract
<bold>Rationale: </bold>The optimal strategy for the diagnosis of latent tuberculosis infection is controversial. Adoption of a two-step strategy (tuberculin skin test [TST] followed by an IFN-gamma release assay [IGRA], compared with an IGRA alone), may be limited by TST-mediated boosting of subsequent IGRA responses. Assessment of within-subject IGRA variability will aid in establishing thresholds for conversions and reversions, and interpretation of serial testing results.<bold>Objectives: </bold>To determine short-term IGRA variability and the impact of TST on subsequent IGRA results.<bold>Methods: </bold>Within-subject variability and TST-mediated boosting of IGRA responses were evaluated in 26 South African participants with varying exposure risk. IGRAs (T-SPOT.TB, QuantiFERON-TB Gold In-Tube [QuantiFERON-TB-GIT], PPD, and heparin-binding hemagglutinin) were repeated four times over 21 days pre-TST, and on Days 3, 7, 28, and 84 post-TST administration.<bold>Measurements and Main Results: </bold>All participants showed within-subject IGRA variability. Changes of +/-3 spots (T-SPOT.TB) or +/-80% from the mean IFN-gamma response (QuantiFERON-TB-GIT) over 3 weeks explained 95% of the variability. Spontaneous conversions/reversions occurred in 7 of 26 subjects (27%) (6 for T-SPOT.TB and 1 for QuantiFERON-TB-GIT [P = 0.049]) during the within-patient variability studies (pre-TST). After the TST eight subjects (33%) boosted above the defined baseline variability. By Day 7 post-TST, but not Day 3, 2 (12.5%) initially IGRA-negative test subjects converted. By contrast, boosting of PPD and heparin-binding hemagglutinin occurred by Day 3 post-TST.<bold>Conclusions: </bold>When using a two-step screening strategy it appears safe to perform a QuantiFERON-TB-GIT or T-SPOT.TB IGRA within 3 days of performing the TST. A 3-spot or 80% IFN-gamma response variation, on either side of baseline values, explains 95% of the short-term variability and may be useful for interpreting conversions and reversions, and values close to the cut-point.
- Publication
American Journal of Respiratory & Critical Care Medicine, 2009, Vol 180, Issue 1, p49
- ISSN
1073-449X
- Publication type
journal article
- DOI
10.1164/rccm.200811-1704OC